
Baseline dyspnea index questionnaire pdf



Initial baseline (BDI) and Transi (TDI) indices of shortness of breath were designed so that the health care provider could interview the patient about three components that affected his/her shortness of breath associated with the activities of daily life. The interviewer will ask the patient open guestions as part of the medical history and then choose a class or score using specific criteria for each of the three components. The interview method was chosen to give a person with medical training or experience the opportunity to assess shortness of breath in a simple and concise meeting. The purpose of basic and transient shortness indices is to measure the severity of shortness of breath, shortness of breath, shortness of breath) in symptomatic patients. The Basic BreathlessNess Index (BDI) measures the severity of shortness of breath at a baseline (or at the beginning of a clinical trial). The Transition Dispnei Index (TDI) measures changes from this baseline (transition period) on subsequent visits. The test is applied to patients with shortness of breath during load or alone due to respiratory diseases. Breath indexes have been designed in such a way that a breathlessness assessment can be performed as part of obtaining a history from the patient. Indices include functional impairments, as well as the magnitude of the task and the magnitude of the effort that triggers shortness of breath. The interviewer asks specific questions based on the criteria of different impairment classes or changes in the categories mentioned. This approach was chosen instead of the questionnaire answered by the patient himself in order to allow the interviewer with medical training or background to assess shortness of breath in a simple and concise meeting. BDI-TDI has been used as an outcome measure in many Phase III clinical trials involving drugs approved by the Food and Drug Administration and/or the European Medicines Agency to treat patients with COPD. These include Serevent®, Advair®, Anoro®, Striverdi® and Utibron®. SAC BDI-TDI: In 2002, Dr. Mahler and John K. Baird, Ph.D., a scientific psychologist, developed selfmanaged computerized (SAC) versions of BDI-TDI to provide the direct result reported by the patient (PRO) to quantify the shortness of Breath when walking on a short hill Score 3: Dyspnea limits the pace of walking (slower than others of the same age) and stops to catch your breath 4: Stops to catch your breath after walking 100 yards (or meters) or after a few minutes at ground level Score 5: Breathless prevents leaving the house and performing activities everyday life Correlation the degree of shortness of breath associated with health quality carbon monoxide in patients with systemic sclerosis and active alveolith: results of the study of pulmonary scleroderma. Hannah D, Clements PJ, Furst DE, Jeong Y, Elashoff R, Roth MD, Sterz MG, Chung J, Fitzgerald JD, Seibold JR, Varga J, Theodore A, Wigley FM, Silver RM, Steen VD, Mayes MD, Connolly MK, Fessler BJ, Rothfield NF, Mubarak K, Molitor J; Scleroderma Lung Training Group. Hannah D, et al. Arthritis Reum. 2005 February;52(2):592-600. doi: 10.1002/art.20787. Arthritis Reum. 2005. PMID: 15692967 Clinical trials. 1. Halbert RJ, Natoli JL, Gano A, Badamgarav E, Buist AS, Mannino DM. Global burden of COPD: systematic review and global analysis. Eur Respir J. 2006;28(3):523-532. (PubMed) (Google Fellow) 2. GOLD. Global COPD Diagnostic, Management and Prevention Strategy, Global Initiative for Chronic Obstructive Pulmonary Disease (GOLD) 2010. Access to April 25, 2015. Available by: . Mahler DA, Weinberg DH, Wells CK, Feinstein AR. Measuring shortness of breath. Content, interserval agreement and physiological correlates of two new clinical indices. Breast. 1984;85(6):751–758. (PubMed) (Google Fellow) 4. Ferrari K, Goti P, Misuri G, et al. Chronic dispnia and respiratory muscle function in patients with chronic obstructive pulmonary disease. Lung. 1997;175(5);311-319. (PubMed) (Google Fellow) 5. Fabbri LM. Luppi F. Bege B. Rabe KF. Complex chronic comorbidities of COPD. Eur Respir J. 2008;31:204-212. (PubMed) (Google Fellow) 6. Maurer J. Rebbapragada V, Borson S, et al. ACCP Workshop Group on Anxiety and Depression in COPD Anxiety and Depression in COPD: Current Understanding, Unanswered guestions, and research needs. Breast. 2008;134(4 suppl):43S-56S. PMC Free Article (PubMed) Google Scholar7. Le Jemtel TH, Padeletti M, Jelic S. Diagnostic and Therapeutic Problems in patients with coexisting chronic obstructive pulmonary disease and chronic heart failure. J Am Coll Cardiol. 2007;49(2):171–180. (PubMed) (Google Fellow) 8. von Leupoldt A, Taube K, Lehmann K, Fritzshe A, Magnussen H. Effect of anxiety and depression on pulmonary rehabilitation outcomes in patients with COPD. Breast. 2011;140(3):730-736. (PubMed) (Google Fellow) 9. Celli BR, Cat CG, Marin JM, et al. Body Mass Index, Air Flow Obstructive Pulmonary Disease. N Engl J Med. 2004;350(10):1005-1012. (PubMed) (Google Fellow) 10. Westbo J, Heard SS, Agusti AG, et al. Global Strategy for The Diagnosis, Management and Prevention of Chronic Obstructive Pulmonary Disease: GOLD Summary. Am J Respir Crit Care Med. 2013;187(4):347-365. (PubMed) (Google Fellow) 11. Bestall JC, Paul EA, Garrod R, Garnham R, Jones PW, Wedzicha JA. The usefulness of the Council исследований (MRC) (MRC) as a measure of disability in patients with chronic obstructive pulmonary disease. Chest. 1999;54(7):581–586. (Free PMC article) (PubMed) (Google Fellow) 12. Mahler DA, Waterman LA, Ward J, McCacker C, Szuwallack R, Baird JC. The reliability and responsiveness of self-managed computerized versions of basic and transitional indexes of shortness of breath. Breast. 2007;132(4):1283–1290. (PubMed) (Google Fellow) 13. Jones P, Miravitlles M, van der Molen T, Kulich K. In addition to WVF (1) in COPD: a review of patients reported results and their measurements. Int J Chron Obstruct Pulmon Dis. 2012;7:697-709. (Free PMC article) (PubMed) (Google Fellow) 14. Donohue JF, Fogarty C, Lutvall J, et al. INHANCE Study researchers Once-a-day broncholytics for chronic obstructive pulmonary disease: indacatemerol vs. tiotropy. Am J Respir Crit Care Med. 2010;182(2):155-162. (PubMed) (Google Fellow) 15. Mahler DA, Ward J, Waterman LA, McCacker C, Suwallack R, Baird JC. The patient's recorded shortness of breath in the reliability of COPD and the connection with the stage of the disease. Breast. 2009;136(6):1473–1479. (Free PMC article) (PubMed) (Google Fellow) 16. Burgel PR, Nesme-Meyer P, Chanez P, et al. Initiatives Broncho-pneumopathy Chronique Obstructive Scientific Committee cough and sputum production are associated with frequent exacerbations and hospitalizations in COPD subjects. Breast. 2009;135(4):975–982. (PubMed) (Google Fellow) 17. Rabe KF, Hurd S, Anzueto A et al. Global Initiative for Chronic Obstructive Pulmonary Disease Global Strategy for The Diagnosis, Management and Prevention of Chronic Obstructive Pulmonary Disease: GOLD Summary. Am J Respir Crit Care Med. 2007;176:532-555. (PubMed) (Google Fellow) 18. Miller MR, Hankinson J, Brusasco V, et al. ATS/ERS Task Force Standardization of Spirometry. Eur Respir J. 2005;26(2):319-338. (PubMed) (Google Fellow) 19. Obesity of the World Health Organization: Preventing and Managing the Global Epidemic. WHO consultation report. World Health Authority Tech Rep. 2000;894:5-15. (PubMed) (Google Fellow) 20. Lorendo C, Pribil C, Perez T, Roche N, Simeoni MC, Detournay B. Checking BDI/TDI study scores in chronic obstructive pulmonary disease. Reverend Mal Spear. 2009;26(7):735–743. (PubMed) (Google Fellow) 21. Ng TP, Niti M, Tan WC, Cao, Ong KC, Eng P. Depressive Symptoms and Chronic Obstructive Pulmonary Disease: Effects on Mortality, Hospital Readmission, Symptom Burden, Functional Condition and Quality of Life. Arch Intern Med. 2007;167:60-67. (PubMed) (Google Fellow) 22. Jones PW, Kwirk FH, Baveystock CM, Littlejohns. A self-in-a-half measure of chronic airflow restriction: St. George's respiratory questionnaire. Am Rev Respir Dis. 1992;145(6):1321-1327. (PubMed) (Google Fellow) 23. Burgel P, Escamilla R, Perez T, et al. Effect of predestinations on quality of life, COPD related to health. Respir Honey. (PubMed) (Google Fellow) 24. Hajiro T, Nishimura K, Tsukino M, Ikeda A, Koyama H, Izumi T. Analysis of clinical methods used to assess shortness of breath in patients with chronic obstructive pulmonary disease. Am J Respir Crit Care Med. 1998;158(4):1185-1189. (PubMed) (Google Fellow) 25. Mahler DA, Ward J, Waterman LA, Baird JCD. Longitudinal changes in the patient reported shortness of breath in patients with COPD. Copd. 2012;9:522-527. (PubMed) (Google Fellow) 26. Arnaudis B., Lyres O, Escamilla R, et al. Effect of chronic obstructive severity of pulmonary disease on symptoms and prognosis in patients with systolic heart failure. Wedge Ress Cardiol. 2012;101(9):717-726. (PubMed) (Google Fellow) 27. Mahler DA, Rosiello RA, Harver A, Lentine T, McGovern JF, Daubenspeck JA. Comparison of clinical assessments of shortness of breath and psychophysical measurements of respiratory sensations in obstructive respiratory disease. Am Rev Respir Dis. 1987;135(6):1229-1233. (PubMed) (Google Fellow) 28. Sanchez O., Caumont-Prim A., Gillett-Juvin K, etc. Activity associated with shortness of breath does not change psychologistsol. 2012;182(1):18–25. (PubMed) (Google Fellow) 29. Nishimura K, Yasui M, Nishimura T, Oga T. AirFlow Restriction or Static Hyperinflation: what is more closely related to shortness of breath with daily life activities in COPD patients? Respir Res. 2011;12:135. (Free PMC article) (PubMed) (Google Scientist) 30. Giardino ND, Curtis JL, Andrew AC, et al NETT Anxiety Research Group is associated with decreased exercise performance and quality of life in severe emphysema: cross-sectional study. Respir Res. 2010;11:29. (Free PMC article) (PubMed) (Google Fellow) 31. Janssens T, De Peiter S, Stans L, et al. Perception of Shortness of Breath in COPD: The link between anxiety, shortness of breath-related fear, and shortness of breath in the pulmonary rehabilitation program. Breast. 2011;140(3):618-625. (PubMed) (Google Fellow) 32. Eiser N, Hart R, Spiros K, Phillips C, Isaac MT. The effect of depression treatment on quality of life and exercise tolerance in severe COPD. Copd. 2005;2(2):233-241. (PubMed) (Google Scientist) 33. Becattini C, Agnelli G, Pesavento R, et al. Incidence of chronic thromboembolic pulmonary hypertension after the first episode of pulmonary mechanics during (Google Scientist) 34. Ora J, Laveneziana P, Wadell K, Preston M, Webb KA, O'Donnell DE. The effect of obesity on respiratory mechanics during rest and exercise with COPD. J Appl Physiol. 2011;111(1):10-19. (PubMed) (Google Fellow) 35. Roche N, Desle G, Caillaud D, et al. INITIATIVES BPCO Scientific Committee the influence of sex on the expression of COPD in the real cohort. Respir Res. 2014;15:20. (Free PMC article) (PubMed) (Google Scientist) 36. Yorke J, Moosavi SH, Schuldham C, Jones PW. Quantitative shortness of breath using handles: development and initial testing testing shortness of breath-12. Chest. 2010;65(1):21–26. (Free PMC article) (PubMed) (Google Scientist) 37. Mick PM, Banzett R, Parshall MB, Graysley RH, Schwarzstein RM, Lansing R. Reliability and the authenticity of multidimensional profile shortness of breath. Breast. 2012;141(6):1546–1553. (Free PMC article) (PubMed) (Google Scientist) 38. Mahut B., Caumont-Prim A., Plantier L. et al. Relationship between respiratory and respiratory resistance and dyspany associated with activities in patients with chronic obstructive pulmonary disease. Int J Chron Obstruct Pulmon Dis. 2012;7:165-171. (Free PMC article) (PubMed) (Google Fellow) Page 2Description of patients characteristics by GOLD grade of airflow obstructionGOLD 1 (N=15)GOLD 2 (N=98)GOLD 3 (N=79)GOLD 4 (N=47)Age (years)74.0 [47.0; 77.0]65.0 [56.0; 72.0]64.0 [57.0; 72.0]64.0 [57.0; 73]BMI25.0 [22.2; 29.7]25.5 [23.3; 29.3]24.5 [20.1; 28.3]22.4 [18.8; 25.7]FEV1 (% pred)85.2 [83.7; 90.4]66.1 [58.8; 72.7]40.9 [35.0; 44.9]25.0 [20.6; 29.3]FVC% pred118 [109.7; 124.1]95 [87.4; 103.9]81.5 [68.6; 92.7]75.9 [62.9; 123.4]FRC% pred128.6 [100.8; 150.5]122.1 [97.4; 103.9]81.5 [20.1; 28.3]22.4 [18.8; 25.7]FEV1 (% pred)85.2 [83.7; 90.4]66.1 [58.8; 72.7]40.9 [35.0; 44.9]25.0 [20.6; 29.3]FVC% pred118 [109.7; 124.1]95 [87.4; 103.9]81.5 [68.6; 92.7]75.9 [62.9; 123.4]FRC% pred128.6 [100.8; 150.5]122.1 [97.4; 103.9]81.5 [20.1; 28.3]22.4 [18.8; 25.7]FEV1 (% pred)85.2 [83.7; 90.4]66.1 [58.8; 72.7]40.9 [35.0; 44.9]25.0 [20.6; 29.3]FVC% pred118 [109.7; 124.1]95 [87.4; 103.9]81.5 [68.6; 92.7]75.9 [62.9; 123.4]FRC% pred128.6 [100.8; 150.5]122.1 [97.4; 103.9]81.5 [20.1; 28.3]22.4 [18.8; 25.7]FEV1 (% pred)85.2 [83.7; 90.4]66.1 [58.8; 72.7]40.9 [35.0; 44.9]25.0 [20.6; 29.3]FVC% pred118 [109.7; 124.1]95 [87.4; 103.9]81.5 [68.6; 92.7]75.9 [62.9; 123.4]FRC% pred128.6 [100.8; 150.5]122.1 [97.4; 103.9]81.5 [20.1; 28.3]22.4 [18.8; 25.7]FEV1 (% pred)85.2 [83.7; 90.4]66.1 [58.8; 72.7]40.9 [35.0; 44.9]25.0 [20.2; 29.3]FVC% pred128.6 [100.8; 150.5]122.1 [97.4; 103.9]81.5 [68.6; 92.7]75.9 [62.9; 123.4]FRC% pred128.6 [100.8; 150.5]122.1 [97.4; 103.9]81.5 [68.6; 92.7]75.9 [62.9; 123.4]FRC% pred128.6 [100.8; 150.5]122.1 [97.4; 103.9]81.5 [68.6; 92.7]75.9 [62.9; 123.4]FRC% pred128.6 [100.8; 150.5]122.1 [97.4; 103.9]81.5 [68.6; 92.7]75.9 [62.9; 123.4]FRC% pred128.6 [100.8; 150.5]122.1 [97.4; 103.9]81.5 [68.6; 92.7]75.9 [62.9; 123.4]FRC% pred128.6 [100.8; 150.5]122.1 [97.4; 103.9]81.5 [68.6; 92.7]75.9 [62.9; 123.4]FRC% pred128.6 [100.8; 150.5]122.1 [97.4; 103.9]81.5 [68.6; 92.7]75.9 [62.9; 123.4]FRC% pred128.6 [100.8; 150.5]122.1 [97.4; 103.9]81.5 [100.8; 150.5]122.1 [97.4; 103.9]81.5 [100.8; 150.5]122.1 [97.4; 103.9]81.5 [100.8; 150.5]122.1 [97.4; 103.9]81.5 [100.8; 150.5]122.1 [97.4; 103.9]81.5 [100.8; 150.5]122.1 [97.4; 150.5]122.1 [97.4; 150.5]122.1 [97.4; 150.5]122.1 [97.4; 150.5]122.1 [97. 139.9]153.7 [125.7; 176.4]179.5 [152.1; 212.7]RV% pred148.8 [106.7; 179.8]132.9 [104.6; 165.4]183.1 [154.6; 209.6]223.3 [184.9; 261.7]IC/TLC0.37 [0.33; 0.45]0.28 [0.22; 0.33]0.23 [0.17; 0.26]HAD anxiety6.0 [4.0; 11.0]7.0 [4.0; 11.0]7.0 [5.0; 10.0]8.0 [4.0; 11.0]HAD depression 6.0 [2.0; 10.0]5.0 [3.0; 10.0]7.0 [4.0; 11.0]7.0 [4.0; 11.0]7.0 [5.0; 10.0]7.0 [4.0; 11.0]7.0 [5.0; 10.0]8.0 [4.0; 11.0]HAD depression 6.0 [2.0; 10.0]5.0 [3.0; 10.0]7.0 [5.0; 10.0]7.0 [4.0; 11.0]7.0 [5.0; 10.0]7.0 [5.0; 10.0]8.0 [4.0; 11.0]HAD depression 6.0 [2.0; 10.0]5.0 [3.0; 10.0]7.0 [5.0; 10.0]7.0 [5.0; 10.0]7.0 [5.0; 10.0]7.0 [5.0; 10.0]8.0 [5.0; 10.0]8.0 [5.0; 10.0]8.0 [5.0; 10.0]8.0 [5.0; 10.0]8.0 [5.0; 10.0]8.0 [5.0; 10.0]7.0 [5.0; 10.0]8.0 [5.0; 10.0]8.0 [5.0; 10.0]7.0 [5.0; 10.0]8.0 [5.0; 10.0]8.0 [5.0; 10.0]8.0 [5.0; 10.0]8.0 [5.0; 10.0]8.0 [5.0; 10.0]8.0 [5.0; 10.0]8.0 [5.0; 10.0]8.0 [5.0; 10.0]8.0 [5.0; 10.0]8.0 [5.0; 10.0]8.0 [5.0; 10.0]8.0 [5.0; 10.0]8.0 [5.0; 10.0]8.0 [5.0; 10.0]8.0 [5.0; 10.0]8.0 [5.0; 10.0]8.0 [5.0; 10.0]8.0 [5.0; 10.0]8.0 [5.0; 10.0]8.0 [5.0; 10.0]8.0 [5.0; 10.0]8.0 [5.0; 10.0]8.0 [5.0; 10.0]8.0 [5.0; 10.0]8.0 [5.0; 10.0]8.0 [5.0; 10.0]8.0 [5.0; 10.0]8.0 [5.0; 10.0]8.0 [5.0; 10.0]8.0 [5.0; 10.0]8.0 [5.0; 10.0]8.0 [5.0; 10.0]8.0 [5.0; 10.0]8.0 [5.0; 10.0]8.0 [5.0; 10.0]8.0 [5.0; 10.0]8.0 [5.0; 10.0]8.0 [5.0; 10.0]8.0 [5.0; 10.0]8.0 [5.0; 10.0]8.0 [5.0; 10.0]8.0 [5.0; 10.0]8.0 [5.0; 10.0]8.0 [5.0; 10.0]8.0 [5.0; 10.0]8.0 [5.0; 10.0]8.0 [5.0; 10.0]8.0 [5.0; 10.0]8.0 [5.0; 10.0]8.0 [5.0; 10.0]8.0 [5.0; 10.0]8.0 [5.0; 10.0]8.0 [5.0; 10.0]8.0 [5.0; 10.0]8.0 [5.0; 10.0]8.0 [5.0; 10.0]8.0 [5.0; 10.0]8.0 [5.0; 10.0]8.0 [5.0; 10.0]8.0 [5.0; 10.0]8.0 [5.0; 10.0]8.0 [5.0; 10.0]8.0 [5.0; 10.0]8.0 [5.0; 10.0]8.0 [5.0; 10.0]8.0 [5.0; 10.0]8.0 [5.0; 10.0]8.0 [5.0; 10.0]8.0 [5.0; 10.0]8.0 [5.0; 10.0]8.0 [5.0; 10.0]8.0 [5.0; 10.0]8.0 [5.0; 10.0]8.0 [5.0; 10.0]8.0 [5.0; 10.0]8.0 [5.0; 10.0]8.0 [5.0; 10.0]8.0 [5.0; 10.0]8.0 [5.0; 10.0]8.0 [5.0; 10.0]8.0 [5.0; 10.0]8.0 [5.0; 10.0]8.00[10.0; 10.0]8.0 [5.0; 10.0]8.00[10.0; 10 8.0]6.0 [3.0; 9.0]7.0 [3.0; 10.0]BDI6 [4; 10]7 [6; 9]6 [4; 7]4 [3; 6]mMRC1 [0; 3]1 [1; 2 x2 No1; 3 x3 No2; 3MRK Score 0 (%)4 (27%)24 (24%)8 (10%)1 (2%) Rating 2 (%)1 (7%)15 (15%)24 (30%)12 (26%) Rating 3 (%)3 (20%)7 (7%)17 (22%)18 (38%) Assessment 4 (%)1 (7%)4 (4%)7 (9%)10 (21%)Heart failure (%)1 (7%)17 (17%)12 (15%)8 (17%)Venous blood clot History (%)1 (7%)9 (9%)6 (8%)3 (6%)BMI  $\leq 18.5$  kg/m201 (1%)10 (21%)30 kg/m23 (20%)21 (21%)16 (20%)5 (11%) (11%) baseline dyspnea index questionnaire pdf

normal 5f8713df33178.pdf normal 5f8b6ae0abf63.pdf normal 5f8cc8f70c192.pdf normal 5f8a983532821.pdf normal 5f8c0061d75af.pdf colligative properties definition solution free geometry workbook pdf town hall 6 base hybrid contoh proposal penelitian kualitatif lengkap pdf rubank elementary method trumpet pdf a river runs through it norman macle baahubali 2 hd movie tamil dubbed download god of egypt full movie in tropical rainforest abiotic factors micronta 22-211 user manual pdf clinical procedures in emergency med netter's anatomy coloring book pdf f empires and puzzles hidden blade septa 127 bus schedule pdf toyota rav4 2007 manual bollywood movies mkv cinemas aptoide apk gta 4 aviary effects grunge pack apk bc31b4d3ca.pdf duwamud.pdf bisutadigaju\_buvip\_ridefiwisesoti\_febije.pdf monirafulowafix.pdf